Prediction of possible new drug binding site for ATP-sensitive potassium channel inhibition: bupropion's modulation of hippocampal CA1 neuron excitability.
Journal:
Neuroreport
Published Date:
Jul 10, 2025
Abstract
OBJECTIVE: Bupropion, a norepinephrine-dopamine reuptake inhibitor, is widely used as an antidepressant and smoking cessation aid. At high doses, it also inhibits pancreatic β-cell ATP-sensitive potassium (KATP) channels, inducing insulin secretion. KATP channels are also expressed in the brain, and their gain-of-function mutations cause neurological disorders such as developmental delay, epilepsy, and neonatal diabetes (DEND syndrome). This study investigates bupropion's effects on KATP channels in mouse hippocampal CA1 pyramidal neurons.
